세계의 로사르탄 시장 보고서(2025년)
Losartan Global Market Report 2025
상품코드 : 1760598
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,469,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,350,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,232,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

로살탄의 시장 규모는 향후 몇 년 동안 안정적인 성장세를 보이며 2029년까지 4.6%의 CAGR로 17억 9,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 비용 효율적인 항고혈압제에 대한 수요 증가, 예방 의료에 대한 관심 증가, 생활습관병 유병률 증가, 신흥 시장에서의 의료 접근성 확대, 제네릭 의약품의 지속적인 출시 등의 요인에 기인하는 것으로 보입니다. 이 기간 동안 주요 동향으로는 약물전달의 발전, 복합제 개발, 제제 기술 혁신, 제조 공정 개선, 맞춤형 의료 접근법 개발 등을 꼽을 수 있습니다.

고혈압 유병률의 증가는 가까운 장래에 로사르탄 시장의 확장을 주도할 것으로 예상됩니다. 고혈압은 지속적인 고혈압이 특징이며 심장병, 뇌졸중 및 기타 심각한 건강 문제의 위험을 증가시킵니다. 고혈압의 증가는 종종 소금과 가공 식품이 많은 식습관과 관련이 있으며, 이는 체액 저류를 유발하고 심장에 부담을 증가시킵니다. 로살탄은 혈관을 수축시키는 호르몬인 안지오텐신 II를 차단하여 고혈압 관리에 도움을 줍니다. 이 작용으로 혈관이 이완되고 확장되어 혈압을 낮추고 심장의 부담을 줄입니다. 예를 들어, 미국심장협회의 보고에 따르면 2024년 1월 고혈압으로 인한 사망자 수는 13만 1,454명으로 2021년 12만 4,508명에서 증가했다고 합니다. 이러한 고혈압 유병률의 증가는 로살탄의 수요를 견인하고 있습니다.

로살탄 시장의 주요 기업들은 환자의 순응도를 개선하고 치료 용도를 확대할 수 있는 혁신적인 제품 개발에 주력하고 있습니다. 이러한 혁신적인 제품 중 하나는 로살탄 칼륨 경구 현탁액으로, 정제를 삼키기 어려운 환자를 위해 고안된 로살탄 액상 제제입니다. 2025년 3월, 미국 바이오 제약사 사이언티카 홀딩스는 고혈압 치료, 좌심실 비대를 동반한 고혈압 환자의 뇌졸중 위험 감소, 제2형 당뇨병 환자의 당뇨병성 신질환 관리 제2형 당뇨병 환자의 당뇨병성 신증 관리를 위한 즉시 사용 가능한 액상 제제인 Arbli의 FDA 승인을 받았으며, Arbli는 165mL의 페퍼민트 향이 나는 현탁액(10mg/mL)으로 실온에서 18개월 동안 보관할 수 있는 정확한 투약이 가능하며, 배합제 없이도 정확한 투여가 가능합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 거시경제 시나리오 : 금리·인플레이션·지정학·무역 전쟁·관세·코로나와 회복이 시장에 미치는 영향을 포함한다

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계 시장 : 경쟁 벤치마킹·대시보드

제33장 주요 기업 인수합병(M&A)

제34장 최근의 시장 동향

제35장 시장 잠재력 높은 나라·부문과 전략

제36장 부록

ksm
영문 목차

영문목차

Losartan is an angiotensin II receptor blocker (ARB) commonly prescribed to treat high blood pressure and reduce the risk of stroke in patients with hypertension. It works by relaxing blood vessels, which makes it easier for the heart to pump blood. Losartan helps lower blood pressure, improves heart function, and protects kidney health, particularly in patients with diabetes.

The primary forms of losartan dosage include tablets, powder, and suspension. Losartan tablets are convenient, once-daily oral medications used to manage hypertension and diabetic nephropathy. It is sourced from various suppliers, including contract manufacturing organizations and in-house production, and is distributed through both online and offline channels. Losartan is used for a range of conditions, including hypertension, stroke, diabetic nephropathy, and more. It is suitable for use by a variety of end-users, including both adults and pediatrics.

The losartan market research report is one of a series of new reports from The Business Research Company that provides losartan market statistics, including the losartan industry global market size, regional shares, competitors with the losartan market share, detailed losartan market segments, market trends, and opportunities, and any further data you may need to thrive in the losartan industry. This losartan market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The losartan market size has grown steadily in recent years. It will grow from $1.44 billion in 2024 to $1.50 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth during the historic period can be attributed to factors such as the increasing geriatric population, rising healthcare expenditure, a rise in diabetic nephropathy cases, greater awareness of blood pressure management, and the growing adoption of generic ARBs.

The losartan market size is expected to see steady growth in the next few years. It will grow to $1.79 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth during the forecast period can be attributed to factors such as the increasing demand for cost-effective antihypertensive drugs, a growing focus on preventive healthcare, the rising prevalence of lifestyle-related disorders, expanded healthcare access in emerging markets, and the continuous launch of generic formulations. Key trends during this period include advancements in drug delivery systems, the development of fixed-dose combination therapies, innovation in formulation technologies, improved manufacturing processes, and the development of personalized medicine approaches.

The growing prevalence of hypertension is expected to drive the expansion of the losartan market in the near future. Hypertension, characterized by persistently high blood pressure, increases the risk of heart disease, stroke, and other serious health issues. The rise in hypertension is often linked to diets rich in salt and processed foods, which cause fluid retention and increase the strain on the heart. Losartan helps manage hypertension by blocking angiotensin II, a hormone that narrows blood vessels. This action relaxes and widens the vessels, lowering blood pressure and reducing the heart's burden. For example, the American Heart Association reported that in January 2024, there were 131,454 deaths primarily associated with high blood pressure in 2022, an increase from 124,508 deaths in 2021. This rising prevalence of hypertension is driving the demand for losartan.

Major companies in the losartan market are focusing on creating innovative products to improve patient compliance and expand therapeutic uses. One such innovation is the losartan potassium oral suspension, a liquid form of losartan designed for people who find it difficult to swallow tablets. In March 2025, Scienture Holdings Inc., a US-based biopharmaceutical company, received FDA approval for Arbli, a ready-to-use liquid formulation for treating hypertension, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and managing diabetic nephropathy in type 2 diabetes patients. Arbli offers precise dosing without the need for compounding and comes in a 165 mL peppermint-flavored suspension (10 mg/mL), with an 18-month shelf life at room temperature.

In April 2025, Scienture Holdings, Inc. formed a partnership with Saptalis Pharmaceuticals to manufacture Arbli, a losartan potassium oral suspension (10 mg/mL). This collaboration includes warehousing and distribution agreements with strategic partners to ensure the successful market launch of the first FDA-approved ready-to-use oral liquid losartan, addressing the unmet needs in hypertension treatment. Saptalis Pharmaceuticals, based in the United States, is a key partner in this initiative.

Major players in the losartan market are Viatris Inc., Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Vasudha Pharma Chem Ltd., Unichem Laboratories Ltd., Global Pharma Tek, Manus Aktteva Biopharma LLP, Emcure Pharmaceuticals Ltd., Wellona Pharma, JPM Pharma & Chemicals Pvt. Ltd.

North America was the largest region in the losartan market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in losartan report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the losartan market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The losartan market consists of sales of losartan potassium tablets, losartan-hydrochlorothiazide combination tablets, and generic formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Losartan Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on losartan market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for losartan ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The losartan market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Losartan Market Characteristics

3. Losartan Market Trends And Strategies

4. Losartan Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Losartan Growth Analysis And Strategic Analysis Framework

6. Losartan Market Segmentation

7. Losartan Market Regional And Country Analysis

8. Asia-Pacific Losartan Market

9. China Losartan Market

10. India Losartan Market

11. Japan Losartan Market

12. Australia Losartan Market

13. Indonesia Losartan Market

14. South Korea Losartan Market

15. Western Europe Losartan Market

16. UK Losartan Market

17. Germany Losartan Market

18. France Losartan Market

19. Italy Losartan Market

20. Spain Losartan Market

21. Eastern Europe Losartan Market

22. Russia Losartan Market

23. North America Losartan Market

24. USA Losartan Market

25. Canada Losartan Market

26. South America Losartan Market

27. Brazil Losartan Market

28. Middle East Losartan Market

29. Africa Losartan Market

30. Losartan Market Competitive Landscape And Company Profiles

31. Losartan Market Other Major And Innovative Companies

32. Global Losartan Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Losartan Market

34. Recent Developments In The Losartan Market

35. Losartan Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기